Efficacy
At Week 48, brolucizumab demonstrated non-inferiority to aflibercept in mean BCVA change from baseline in HAWK (p<0.001). • Visual acuity gains achieved at Week 48...
At Week 48, brolucizumab demonstrated non-inferiority to aflibercept in mean BCVA change from baseline in HAWK (p<0.001). • Visual acuity gains achieved at Week 48...
MONALEESA-2 OS BY DOSE REDUCTION poster discussion | Hart LL In this exploratory analysis of ML-2, 1L RIB + LET maintained OS benefit in postmenopausal pts with HR+, HER2...
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report...
Revolade dosing requirements must be individualised based on the patient's platelet counts. The lowest dose of eltrombopag to achieve and maintain a platelet count ≥50,000/µl should be used,...
Two phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325)...